CN101278980A - A kind of quaternary ammonium total alkali and preparation method thereof - Google Patents
A kind of quaternary ammonium total alkali and preparation method thereof Download PDFInfo
- Publication number
- CN101278980A CN101278980A CNA2007101874652A CN200710187465A CN101278980A CN 101278980 A CN101278980 A CN 101278980A CN A2007101874652 A CNA2007101874652 A CN A2007101874652A CN 200710187465 A CN200710187465 A CN 200710187465A CN 101278980 A CN101278980 A CN 101278980A
- Authority
- CN
- China
- Prior art keywords
- quaternary ammonium
- corydalis
- preparation
- total alkali
- rhizoma corydalis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001453 quaternary ammonium group Chemical group 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000003513 alkali Substances 0.000 title claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 121
- 241000218176 Corydalis Species 0.000 claims abstract description 70
- 238000000605 extraction Methods 0.000 claims abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 23
- 239000011347 resin Substances 0.000 claims abstract description 22
- 229920005989 resin Polymers 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 19
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000706 filtrate Substances 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims abstract description 13
- 229910021529 ammonia Inorganic materials 0.000 claims abstract description 9
- 238000009210 therapy by ultrasound Methods 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000010992 reflux Methods 0.000 claims abstract description 7
- 239000006228 supernatant Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 18
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003729 cation exchange resin Substances 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 3
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003463 adsorbent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 238000007654 immersion Methods 0.000 claims 1
- 238000004062 sedimentation Methods 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 abstract description 17
- 239000012535 impurity Substances 0.000 abstract description 9
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 239000000047 product Substances 0.000 abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 239000002585 base Substances 0.000 description 19
- 238000001179 sorption measurement Methods 0.000 description 10
- 238000002791 soaking Methods 0.000 description 7
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- 150000003512 tertiary amines Chemical class 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 4
- 229940093265 berberine Drugs 0.000 description 4
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 3
- -1 collect the eluate Substances 0.000 description 3
- XYHOBCMEDLZUMP-UHFFFAOYSA-N coptisine Chemical compound C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 XYHOBCMEDLZUMP-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- XCYSWQAERMXFGO-UHFFFAOYSA-N 1h-benzimidazole;isoquinoline Chemical class C1=CC=C2NC=NC2=C1.C1=NC=CC2=CC=CC=C21 XCYSWQAERMXFGO-UHFFFAOYSA-N 0.000 description 1
- DWKUMZAEOMRJQX-UHFFFAOYSA-N 3h-2-benzofuran-1-one;isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21.C1=CC=C2C(=O)OCC2=C1 DWKUMZAEOMRJQX-UHFFFAOYSA-N 0.000 description 1
- ZPLCXHWYPWVJDL-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(O)=CC=C1CC1NC(=O)OC1 ZPLCXHWYPWVJDL-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- UICBHOXXGLYZJH-UHFFFAOYSA-N 5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium Chemical compound C1=CC=C2CC[N+]3=CC4=CC=CC=C4C=C3C2=C1 UICBHOXXGLYZJH-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000001729 Ammonium fumarate Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 241001532196 Cordyline Species 0.000 description 1
- 241000830532 Corydalis yanhusuo Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 235000019297 ammonium fumarate Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- OWUNMSGLMUPGEZ-UHFFFAOYSA-N benzo[k]phenanthridine Chemical compound C1=CC=CC2=C3C4=CC=CC=C4C=CC3=CN=C21 OWUNMSGLMUPGEZ-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- IZTUINVRJSCOIR-UHFFFAOYSA-N benzylisoquinoline Chemical compound N=1C=CC2=CC=CC=C2C=1CC1=CC=CC=C1 IZTUINVRJSCOIR-UHFFFAOYSA-N 0.000 description 1
- 150000003836 berberines Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- LJSOLTRJEQZSHV-UHFFFAOYSA-L potassium;sodium;hydron;hydroxide;phosphate Chemical compound [OH-].[Na+].[K+].OP(O)([O-])=O LJSOLTRJEQZSHV-UHFFFAOYSA-L 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种延胡索季铵总碱的制备方法。该方法包括延胡索浸泡时采用超声波处理,回流或微波条件下进行季铵碱成分的提取,所得提取液回收乙醇后,经过已处理好的树脂柱进行交换、吸附,用氨醇溶液或含水乙醇洗脱,洗脱液减压浓缩,干燥,干燥物再以含水乙醇复溶,抽滤或离心,滤液或上清液减压浓缩,干燥制成延胡索季铵总碱。应用该方法制备的延胡索季铵总碱提取效率高、杂质含量少,成本低,特别适用于药材提取物、中药单方或含延胡索复方新制剂的大量生产。本发明制备的延胡索季铵总碱,疗效确切,可用于心脑血管疾病的预防和治疗。
The invention discloses a preparation method of total base of quaternary ammonium corydalis. The method comprises the steps of ultrasonic treatment when Corydalis is soaked, extraction of quaternary ammonium base components under reflux or microwave conditions, the resulting extract is recovered from ethanol, exchanged and adsorbed through a treated resin column, and washed with ammonia alcohol solution or aqueous ethanol. The eluate is concentrated under reduced pressure, dried, and the dried product is redissolved with ethanol containing water, filtered or centrifuged, the filtrate or supernatant is concentrated under reduced pressure, and dried to produce total base of quaternary ammonium corydalis. The quaternary ammonium total base of Corydalis prepared by the method has high extraction efficiency, less impurity content and low cost, and is especially suitable for mass production of medicinal material extracts, single prescriptions of traditional Chinese medicines or new compound preparations containing Corydalis Corydalis. The corydalis quaternary ammonium total alkaloid prepared by the invention has definite curative effect and can be used for the prevention and treatment of cardiovascular and cerebrovascular diseases.
Description
技术领域 technical field
本发明涉及一种中药有效部位的提取分离方法,尤其是从中药延胡索中提取分离有效部位季铵总碱的方法。The invention relates to a method for extracting and separating effective parts of traditional Chinese medicine, in particular to a method for extracting and separating effective parts of quaternary ammonium total alkaloids from Chinese medicine Corydalis Corydalis.
背景技术 Background technique
延胡索习称元胡,中国药典载其正品来源为罂粟科(Papaveraeeae)紫堇属(Corydalis)植物延胡索(Corydalis yanhusuo W.T.Wang)的干燥块茎,具有活血散瘀、行气止痛的功效。延胡索作为传统镇痛药和活血化瘀药在我国医药学的应用中已有两千多年的历史,延胡索的化学成分目前发现的主要是生物碱,研究也较多,至今共从其块茎中发现二十五种,按其化学结构可分为原小檗碱类、原托品碱类、阿朴菲类、苯并菲啶类、苯酞异喹啉类、苄基异喹啉类、异喹啉苄咪唑啉类等几种类型的生物碱,其中多数属原小檗碱类和阿朴菲类。如按其氨基氮的性质划分则可分为叔胺碱和季铵碱两大类。目前,对延胡索的研究仍多局限于延胡索乙素或其衍生物等叔胺碱的研究,近代对延胡索的研究主要集中于中枢神经系统方面,延胡索中的叔胺碱类多显示镇痛、镇静及安定作用,延胡索乙素为代表化合物;如将延胡索乙素脱氢转化为相应的季铵碱(棕榈碱),即失去其镇痛、镇静作用,相反,小檗碱氢化成相应的叔胺碱,就显示较强的镇痛和镇静作用,说明它们的药理作用与其氨基氮的性质密切相关。我国古代医籍较多提到使用延胡索治疗心痛、胸痹,现代在治疗心血管疾病的方剂中亦广泛应用,现代药理研究证明,延胡索能显著增加冠脉血流量,改善心肌缺血、缺氧,从而缓解心绞痛。延胡索对心血管系统有显著作用的主要是以脱氢紫堇碱为代表的原小檗碱型季铵生物碱类成分。Corydalis is commonly known as Yuanhu, and the Chinese Pharmacopoeia records that its authentic source is the dry tuber of Corydalis yanhusuo W.T.Wang, a plant of the family Papaveraeeae (Corydalis), which has the effects of promoting blood circulation, removing blood stasis, promoting qi and relieving pain. Corydalis Corydalis as a traditional analgesic and blood-activating and stasis-removing drug has been used in Chinese medicine for more than two thousand years. The chemical components of Corydalis Corydalis are mainly alkaloids, and there are many studies. Twenty-five species were found, which can be divided into protoberberine, prototropine, aporphenanthrene, benzophenanthridine, phthalide isoquinoline, benzyl isoquinoline, Several types of alkaloids such as isoquinoline benzimidazolines, most of which belong to protoberberines and aporberines. According to the nature of its amino nitrogen, it can be divided into two categories: tertiary amine base and quaternary ammonium base. At present, the research on Corydalis is still mostly limited to the research on tertiary amine bases such as tetrahydropalmatine or its derivatives. Modern research on Corydalis mainly focuses on the central nervous system. The tertiary amine bases in Corydalis mostly show analgesia and sedation and stable effect, tetrahydropalmatine is the representative compound; if the dehydrogenation of tetrahydropalmatine is converted into the corresponding quaternary ammonium base (palmitine), it will lose its analgesic and sedative effects. On the contrary, berberine will be hydrogenated into the corresponding tertiary amine Alkalines show strong analgesic and sedative effects, indicating that their pharmacological effects are closely related to the properties of their amino nitrogen. Ancient Chinese medical books often mentioned the use of Corydalis Corydalis to treat heartache and chest obstruction, and it is also widely used in the prescriptions for treating cardiovascular diseases in modern times. Modern pharmacological studies have proved that Corydalis Corydalis can significantly increase coronary blood flow, improve myocardial ischemia and hypoxia, thereby relieving angina. Corydalis Corydalis has a significant effect on the cardiovascular system, mainly the original berberine-type quaternary ammonium alkaloids represented by dehydrocorydine.
目前,文献报道从延胡索药材中提取的总生物碱,多以叔胺碱类成分为主;采用的方法涉及超临界二氧化碳萃取技术(刘龙忠.优选延胡索生物碱提取工艺.遵义医学院学报[J],2004,27(6):595-596.)、超声提取技术(谢彩娟,张志琪.超声提取延胡索总生物碱的研究[J].西北药学杂志,2005,20(4):153-154.)和大孔吸附树脂技术(刘俊红,魏峻峰,王洪志,等.大孔吸附树脂在延胡索生物碱提取分离中的应用[J].中草药,2002,33(1):37-38;张丽筑,朱珠,郝小燕.延胡索生物总碱两种提取方法的比较[J].贵阳医学院学报,2006,31(3):280-282.)等。中国专利申请号200610049743.3公开了一种从延胡索中制备总碱提取物的方法以及用提取物制备的各类制剂,用于治疗急性、慢性的各种疼痛症、镇静、催眠、抗抑郁症。该项发明所涉及的技术方法为:采用5~10%Na2CO3或NaHCO3或NaOH浸湿碱化,又以10~85%乙醇进行提取,提取液减压浓缩,浓缩液又用1~10%HCl或1~10%H2SO4酸化,酸化液进行树脂柱层析,并采用0~90%乙醇洗脱,洗脱液减压浓缩,冷冻干燥,得总生物碱干粉。现有方法中均未提及针对延胡索季铵碱类成分的提取。At present, the literature reports that the total alkaloids extracted from Corydalis Corydalis are mainly composed of tertiary amine bases; the method used involves supercritical carbon dioxide extraction technology (Liu Longzhong. Optimizing the Extraction Process of Corydalis Corydalis. Journal of Zunyi Medical College[J] , 2004, 27(6): 595-596.), ultrasonic extraction technology (Xie Caijuan, Zhang Zhiqi. Ultrasonic extraction of total alkaloids from Corydalis [J]. Northwest Pharmaceutical Journal, 2005, 20(4): 153-154.) and macroporous adsorption resin technology (Liu Junhong, Wei Junfeng, Wang Hongzhi, etc. Application of macroporous adsorption resin in the extraction and separation of Corydalis alkaloids [J]. Chinese Herbal Medicine, 2002, 33(1): 37-38; Zhang Lizhu, Zhu Zhu, Hao Xiaoyan. Comparison of two extraction methods of total alkaloids from Corydalis [J]. Journal of Guiyang Medical College, 2006, 31(3): 280-282.) and so on. Chinese Patent Application No. 200610049743.3 discloses a method for preparing total alkali extract from Corydalis Corydalis and various preparations prepared from the extract, which are used to treat acute and chronic pain, sedation, hypnosis, and antidepression. The technical method involved in this invention is: use 5-10% Na 2 CO 3 or NaHCO 3 or NaOH to soak and alkalize, then extract with 10-85% ethanol, concentrate the extract under reduced pressure, and use 1 ~10% HCl or 1~10% H 2 SO 4 acidification, the acidified solution is subjected to resin column chromatography, and eluted with 0~90% ethanol, the eluate is concentrated under reduced pressure, and freeze-dried to obtain dry powder of total alkaloids. None of the existing methods mentions the extraction of the quaternary ammonium base components of Corydalis.
发明内容 Contents of the invention
本发明的目的是提供一种延胡索季铵总碱的制备方法,本发明针对延胡索提取时季铵类生物碱含量较低问题,通过在浸泡过程中采用了超声波处理,并利用大孔吸附树脂和弱酸性阳离子交换树脂对延胡索季铵碱成分的吸附性质,在解吸前后增加了除杂工序,不仅使得季铵碱成分提取效率大大增加,而且其含量也大幅度提高。The purpose of the present invention is to provide a kind of preparation method of quaternary ammonium total alkaloids of Corydalis. The present invention aims at the problem that the content of quaternary ammonium alkaloids is low when extracting Corydalis, by adopting ultrasonic treatment in the soaking process, and utilizing macroporous adsorption resin and The adsorption properties of the weakly acidic cation exchange resin to the quaternary ammonium component of Corydalis, adding impurity removal procedures before and after desorption, not only greatly increases the extraction efficiency of the quaternary ammonium component, but also greatly increases its content.
本发明的第二个目的是提供一种延胡索季铵总碱,总碱含量在55%以上,其中在延胡索季铵总碱高效液相色谱图中季铵碱成分的峰面积占总峰面积的80%以上,可用于心脑血管疾病的预防和治疗。The second object of the present invention is to provide a kind of total alkali of quaternary ammonium fumarium, and total alkali content is more than 55%, wherein the peak area of quaternary ammonium base composition accounts for 2% of the total peak area in the total peak area of quaternary ammonium fumarium in the high performance liquid chromatography More than 80% can be used for the prevention and treatment of cardiovascular and cerebrovascular diseases.
本发明的目的是通过如下技术方案来实现:The purpose of the present invention is to realize through following technical scheme:
一种延胡索季铵总碱的制备方法,其特征是它包括如下步骤:A kind of preparation method of quaternary ammonium fumarate total alkali is characterized in that it comprises the steps:
(1)将延胡索药材粉末放在含水乙醇中混合浸泡并同时进行超声波处理,浸泡后的混合溶液加热回流提取,或将该混合溶液置微波设备中进行微波辐射提取;(1) mixing and soaking Corydalis Corydalis powder in hydrous ethanol and performing ultrasonic treatment at the same time, heating the mixed solution after soaking to reflux for extraction, or placing the mixed solution in microwave equipment for microwave radiation extraction;
(2)将提取液滤过或离心沉降后,滤液或上清液回收乙醇至无醇味,加水稀释后经过按常规方法已处理好的树脂柱进行交换、吸附;(2) After the extract is filtered or centrifuged, the filtrate or supernatant is recovered from ethanol until it has no alcohol smell, and after being diluted with water, it is exchanged and adsorbed through a resin column that has been treated by a conventional method;
(3)经树脂交换、吸附完毕,先用去离子水或稀碱溶液洗脱,再用氨醇溶液或含水乙醇洗脱,收集洗脱液,洗脱液减压浓缩,干燥;(3) After resin exchange and adsorption are completed, first elute with deionized water or dilute alkali solution, then elute with ammonia alcohol solution or aqueous ethanol, collect the eluate, concentrate under reduced pressure, and dry;
(4)经干燥后的提取物,用含水乙醇复溶,抽滤或离心,滤液或上清液按常规方法回收乙醇,干燥,即得延胡索季铵总碱。(4) The dried extract is redissolved with aqueous ethanol, suction filtered or centrifuged, and the filtrate or supernatant is recovered by conventional methods for ethanol and dried to obtain total base of quaternary ammonium corydalis.
所述的步骤(1)中延胡索药材粉末粒径为5~50目;使用的含水乙醇浓度为30%~95%;加入含水乙醇的量与延胡索按重量比计为1∶2~20。In the step (1), the powder particle size of Corydalis Corydalis is 5-50 meshes; the concentration of hydrous ethanol used is 30%-95%;
所述的步骤(1)中浸泡时间为30~240分钟;使用的超声波频率为20~40KHz。The soaking time in the step (1) is 30-240 minutes; the ultrasonic frequency used is 20-40KHz.
所述的步骤(1)中回流提取时提取时间为1~4小时,提取次数为2~4次。The extraction time during the reflux extraction in the step (1) is 1 to 4 hours, and the extraction times are 2 to 4 times.
所述的步骤(1)中微波提取时微波输出功率为500~800W,辐照时间为10~30分钟,提取温度为50~70℃;提取次数为1~3次。During the microwave extraction in the step (1), the microwave output power is 500-800W, the irradiation time is 10-30 minutes, the extraction temperature is 50-70° C., and the extraction times are 1-3 times.
所述的步骤(2)中使用的树脂为弱酸性阳离子交换树脂,型号为724型或D151型。The resin used in the step (2) is a weakly acidic cation exchange resin, the type of which is 724 or D151.
所述的步骤(2)中使用的树脂为大孔吸附树脂,型号为AB-8型或X-5型。The resin used in the step (2) is a macroporous adsorption resin, and the model is AB-8 or X-5.
所述的步骤(3)中所使用的稀碱溶液为1~10%氨水溶液;氨醇溶液浓度为5%~25%;含水乙醇浓度为30~95%。The dilute alkali solution used in the step (3) is 1-10% ammonia solution; the concentration of ammonia-alcohol solution is 5%-25%; and the concentration of aqueous ethanol is 30-95%.
所述的步骤(4)中所使用的含水乙醇浓度为10~95%。The concentration of the aqueous ethanol used in the step (4) is 10-95%.
一种延胡索季铵总碱,用延胡索季铵总碱的制备方法制成。The invention relates to a total quaternary ammonium corydalis, which is prepared by a preparation method of the total quaternary corydalis ammonium.
本发明的制备方法适合延胡索季铵碱类成分的提取,本发明的工艺先将延胡索药材粉碎,并在浸泡过程中用了超声波处理,它直接影响延胡索药材浸润速度和程度,进而影响季铵碱成分的提取效果;提取工艺采用微波提取,可以极大地缩短提取时间,降低成本,提高生产效率,另外含水乙醇提取也可避免延胡索中过多的水溶性杂质被带到提取液中。提取液回收乙醇后,直接经过树脂柱处理,延胡索季铵碱类成分可以很好地被分离富集,采用稀碱溶液洗脱,可除去大量非生物碱杂质,解析后所得生物碱经含水乙醇复溶,进一步除杂,使得固形物量减小,而延胡索季铵碱类成分含量大幅度增加,从而保证了延胡索季铵总碱提取物的纯度及质量。The preparation method of the present invention is suitable for the extraction of quaternary ammonium base components of Corydalis. The process of the present invention first crushes the medicinal material of Corydalis Corydalis, and uses ultrasonic treatment in the soaking process, which directly affects the infiltration speed and degree of the medicinal material of Corydalis Corydalis, and then affects the quaternary ammonium base The extraction effect of ingredients; the extraction process adopts microwave extraction, which can greatly shorten the extraction time, reduce costs, and improve production efficiency. In addition, aqueous ethanol extraction can also prevent excessive water-soluble impurities in Corydalis Corydalis from being brought into the extract. After the ethanol is recovered from the extract, it is directly treated with a resin column, and the quaternary ammonium base components of Corydalis can be well separated and enriched, and a large amount of non-alkaloid impurities can be removed by elution with a dilute alkali solution. Redissolution and further removal of impurities reduce the amount of solids and increase the content of the quaternary ammonium fumarium alkaloids substantially, thereby ensuring the purity and quality of the total alkaloid extract of the quaternary ammonium fumatillon.
延胡索季铵总碱的鉴定:Identification of quaternary ammonium total bases of Corydalis:
酸性染料法定量分析:以脱氢延胡索碱为对照品,选用pH 8.0的磷酸二氢钾-氢氧化钠缓冲溶液和0.1%溴麝香草酚蓝溶液为显色剂,选用50%甲醇溶液为提取物样品及对照品的溶剂,提取物样品浓度设定在0.2mg/ml,检测波长设定在415nm,回归方程为Y=5.7549X+0.0117,r=0.9991;线性范围为0~0.102mg。所有用本工艺提取所得提取物中总生物碱含量(以脱氢延胡索碱计)均在55%以上。Quantitative analysis by the acid dye method: with dehydrodrycardine as the reference substance, potassium dihydrogen phosphate-sodium hydroxide buffer solution with pH 8.0 and 0.1% bromothymol blue solution as the chromogen, and 50% methanol solution as the extraction agent. The solvent of the sample and the reference substance, the concentration of the extract sample is set at 0.2mg/ml, the detection wavelength is set at 415nm, the regression equation is Y=5.7549X+0.0117, r=0.9991; the linear range is 0~0.102mg. The total alkaloid content (calculated as dehydrodrygosine) in all the extracts extracted by this process is above 55%.
高效液相色谱法定性分析:选用乙腈和水(含0.8%冰醋酸和0.2%三乙胺)为有机和无机流动相,二相的比例为23∶77,流动相流速为1.0ml/min,柱温设定为30℃,检测波长设定为335nm;进样量为10μl。实验中用对照品包括脱氢延胡索碱、小檗碱、黄连碱、巴马汀和非洲防己碱,选用50%甲醇溶液为提取物样品及对照品的溶剂,提取物样品浓度设定在2mg/ml,以对照品高效液相图谱为对照,所有用本工艺提取所得提取物中至少出现7个色谱峰,且脱氢延胡索碱、小檗碱、黄连碱、巴马汀和非洲防己碱均存在,5种季铵碱成分的峰面积共占总峰面积的80%以上。High-performance liquid chromatography qualitative analysis: select acetonitrile and water (containing 0.8% glacial acetic acid and 0.2% triethylamine) as organic and inorganic mobile phases, the ratio of the two phases is 23: 77, and the mobile phase flow rate is 1.0ml/min, The column temperature was set at 30 °C, the detection wavelength was set at 335 nm; the injection volume was 10 μl. The reference substance used in the experiment includes dehydrodrytidine, berberine, coptisine, palmatine and African tetrandrine, and 50% methanol solution is selected as the solvent of the extract sample and the reference substance, and the concentration of the extract sample is set at 2mg/ ml, taking the HPLC chromatogram of the reference substance as a comparison, there are at least 7 chromatographic peaks in all the extracts extracted by this process, and there are dehydrodrycardine, berberine, coptisine, palmatine and African tetrandrine , the peak areas of the five quaternary ammonium base components accounted for more than 80% of the total peak area.
本发明的一种延胡索季铵总碱的制备方法所制备的延胡索季铵总碱可以与一种或多种药学上可接受的载体制成口服剂型或注射剂型,可用于制备预防和治疗心脑血管疾病的药物。The preparation method of total quaternary ammonium corydalis of the present invention can be made into oral dosage form or injection dosage form with one or more pharmaceutically acceptable carriers, and can be used for the preparation of prevention and treatment of heart and brain Drugs for vascular disease.
上面所述药学上可接受的载体是指药学领域常规的药物载体,例如:稀释剂如乳糖、淀粉、糊精、糖粉、微晶纤维素等;粘合剂如纤维素衍生物、明胶、聚乙烯吡咯烷酮等;湿润剂如水、乙醇等;崩解剂如干淀粉、羧甲基淀粉钠、海藻酸钠等;矫味剂如甜叶菊苷、木糖醇等;润滑剂如滑石粉、硬脂酸镁、微粉硅胶等;基质如植物油、聚乙二醇、蜂蜡等;防腐剂如苯甲酸、尼泊金类等。The pharmaceutically acceptable carrier mentioned above refers to the conventional drug carrier in the pharmaceutical field, for example: diluents such as lactose, starch, dextrin, powdered sugar, microcrystalline cellulose, etc.; binders such as cellulose derivatives, gelatin, Polyvinylpyrrolidone, etc.; wetting agents such as water, ethanol, etc.; disintegrants such as dry starch, sodium carboxymethyl starch, sodium alginate, etc.; flavoring agents such as stevioside, xylitol, etc.; lubricants such as talcum powder, hard Magnesium fatty acid, micropowder silica gel, etc.; substrates such as vegetable oil, polyethylene glycol, beeswax, etc.; preservatives such as benzoic acid, paraben, etc.
本发明的一种延胡索季铵总碱的制备方法可以通过口服或注射给药的方式施用于需要这种治疗的患者。可将本发明所制备的延胡索季铵总碱和药学上可接受的载体制成常规的固体或液体制剂如片剂、硬胶囊、软胶囊、滴丸剂、颗粒剂、口服液、注射剂等。The preparation method of the total base of quaternary ammonium corydalis of the present invention can be administered to patients who need such treatment through oral administration or injection. The total base of quaternary ammonium corydalis prepared in the present invention and pharmaceutically acceptable carriers can be made into conventional solid or liquid preparations such as tablets, hard capsules, soft capsules, dropping pills, granules, oral liquids, injections and the like.
本发明的一种延胡索季铵总碱的制备方法所制备的延胡索季铵总碱的使用量可根据患者体重、所治疗的疾病的类型和严重程度情况,其24小时剂量可以是0.5~5mg/kg体重。The usage amount of the total alkaloids of quaternary ammonium corydalis prepared by the preparation method of total quaternary ammonium corydalis of the present invention can be according to the patient's body weight, the type and severity of the disease to be treated, and its 24-hour dose can be 0.5~5mg/ kg body weight.
附图说明 Description of drawings
图1为本发明一种延胡索季铵总碱提取物的高效液相色谱图。Fig. 1 is the high performance liquid phase chromatogram of a kind of Corydalis quaternary ammonium total alkali extract of the present invention.
其中1号峰为非洲防己碱(分子量338),2号峰为蓝堇辛(分子量370),3号峰为黄连碱(分子量320),4号峰(分子量352),5号峰(分子量352),6号峰为巴马汀(分子量352),7号峰为小檗碱(分子量336),8号峰为脱氢延胡索碱(分子量366)。Wherein No. 1 peak is African tetrandrine (molecular weight 338), No. 2 peak is blue cordyline (molecular weight 370), No. 3 peak is coptisine (molecular weight 320), No. 4 peak (molecular weight 352), No. 5 peak (molecular weight 352 ), the No. 6 peak is palmatine (molecular weight 352), the No. 7 peak is berberine (molecular weight 336), and the No. 8 peak is dehydrodrycodine (molecular weight 366).
具体实施方式 Detailed ways
下面结合具体实施例对本发明作进一步的说明,但不以任何方式限制本发明。The present invention will be further described below in conjunction with specific examples, but the present invention is not limited in any way.
实施例1、
延胡索药材粉碎,过5目筛,加入6倍量80%乙醇浸泡同时进行20KHz超声波处理,浸泡时间为60分钟,浸泡后的延胡索药材回流提取法提取3次(6倍,4倍,4倍),每次4小时,合并提取液,滤过除去药渣,滤液回收乙醇至无醇味,药液以去离子水适当稀释,通过X-5型大孔吸附树脂,药液经树脂柱吸附,流速为2毫升/分钟,吸附完毕后,先用2%氨水溶液洗去不吸附的杂质,再用50%乙醇溶液洗脱,收集醇洗脱液,将洗脱液减压浓缩,60℃以下真空干燥,干燥物再用95%乙醇复溶,滤过,滤液减压浓缩,60℃以下真空干燥,即可得到延胡索季铵总碱。Corydalis medicinal material is crushed, passed through a 5-mesh sieve, soaked in 6 times the amount of 80% ethanol and 20KHz ultrasonic treatment, soaking time is 60 minutes, the soaked Corydalis medicinal material reflux extraction method is extracted 3 times (6 times, 4 times, 4 times) , 4 hours each time, combine the extracts, filter to remove the medicinal residues, recover the ethanol from the filtrate until it has no alcohol smell, dilute the medicinal solution with deionized water, pass through the X-5 macroporous adsorption resin, and the medicinal solution is absorbed by the resin column, The flow rate is 2 ml/min. After the adsorption is completed, first wash off the non-adsorbed impurities with 2% ammonia solution, then elute with 50% ethanol solution, collect the alcohol eluate, and concentrate the eluate under reduced pressure. Vacuum drying, redissolving the dried product with 95% ethanol, filtering, concentrating the filtrate under reduced pressure, and vacuum drying below 60°C to obtain the total base of quaternary ammonium corydalis.
实施例2、
延胡索药材粉碎,过5目筛,加入6倍量80%乙醇浸泡同时进行20KHz超声波处理,浸泡时间为60分钟,浸泡后的延胡索药材回流提取法提取3次(6倍,4倍,4倍),每次4小时,合并提取液,滤过除去药渣,滤液回收乙醇至无醇味,药液通过724型弱酸性阳离子交换树脂,滤液经树脂柱吸附、交换的流速为0.5毫升/分钟;交换完毕后,先用水洗去不吸附的杂质,再用20%氨醇溶液洗脱,收集氨醇洗脱液,洗脱过程用生物碱试剂进行检测,洗脱至终点停止加入洗脱液,将洗脱液减压浓缩,60℃以下真空干燥,干燥物用50%乙醇复溶,滤过,滤液减压回收乙醇,60℃以下真空干燥,即可得到延胡索季铵总碱。Corydalis medicinal material is crushed, passed through a 5-mesh sieve, soaked in 6 times the amount of 80% ethanol and 20KHz ultrasonic treatment, soaking time is 60 minutes, the soaked Corydalis medicinal material reflux extraction method is extracted 3 times (6 times, 4 times, 4 times) , 4 hours each time, combine the extracts, filter to remove the medicinal residues, reclaim the ethanol from the filtrate until there is no alcohol smell, the medicinal liquid passes through the 724 type weakly acidic cation exchange resin, and the filtrate is adsorbed and exchanged by the resin column at a flow rate of 0.5 ml/min; After the exchange is completed, first wash away the non-adsorbed impurities with water, then elute with 20% ammonia alcohol solution, collect the ammonia alcohol eluate, use alkaloid reagent to detect the elution process, stop adding eluent until the end of elution, Concentrate the eluate under reduced pressure, dry it in vacuum below 60°C, redissolve the dried product in 50% ethanol, filter, recover the ethanol from the filtrate under reduced pressure, and dry it under vacuum below 60°C to obtain the total base of quaternary ammonium corydalis.
实施例3、
延胡索药材粉碎,过50目筛,加入10倍量70%乙醇浸泡同时进行20KHz超声波处理,浸泡时间为120分钟,浸泡后的延胡索药材置于微波提取罐中,进行微波提取,微波输出功率650W,65℃,辐照10min,提取3次,合并提取液,滤过除去药渣;滤液回收乙醇至无醇味,药液通过AB-8型大孔吸附树脂,滤液经树脂柱吸附;流速为1.5毫升/分钟,吸附完毕后,先用5%氨水溶液洗去不吸附的杂质,再用50%乙醇溶液洗脱,收集醇洗脱液,将洗脱液减压浓缩,60℃以下烘干,干燥物再用95%乙醇复溶,滤过,滤液减压浓缩,60℃的温度下烘干,即可得到延胡索季铵总碱。Corydalis medicinal material is crushed, passed through a 50-mesh sieve, soaked in 10 times the amount of 70% ethanol, and then subjected to 20KHz ultrasonic treatment for 120 minutes. The soaked medicinal material Corydalis Corydalis is placed in a microwave extraction tank for microwave extraction. The output power of the microwave is 650W. 65°C, irradiated for 10 minutes, extracted 3 times, combined the extracts, filtered to remove the medicinal residues; the filtrate recovered ethanol until it had no alcohol smell, the medicinal liquid passed through the AB-8 macroporous adsorption resin, and the filtrate was adsorbed by the resin column; the flow rate was 1.5 mL/min, after the adsorption is completed, first wash away the non-adsorbed impurities with 5% ammonia solution, then elute with 50% ethanol solution, collect the eluate, concentrate the eluate under reduced pressure, and dry it below 60°C. The dry matter is redissolved with 95% ethanol, filtered, the filtrate is concentrated under reduced pressure, and dried at a temperature of 60°C to obtain the total base of quaternary ammonium corydalis.
实施例4、
延胡索药材粉碎,过50目筛,加入10倍量70%乙醇浸泡同时进行20KHz超声波处理,浸泡时间为120分钟,浸泡后的延胡索药材置于微波提取罐中,进行微波提取,微波输出功率650W,65℃,辐照10min,提取3次,合并提取液,滤过除去药渣;滤液回收乙醇至无醇味,药液通过D151型弱酸性阳离子交换树脂,药液经树脂柱吸附、交换的流速为1.0毫升/分钟;交换完毕后,先用水洗去不吸附的杂质,用20%氨醇溶液洗脱,收集氨醇洗脱液,洗脱过程用生物碱试剂进行检测,洗脱至终点停止加入洗脱液,将洗脱液减压浓缩,60℃以下真空干燥,干燥物用50%乙醇复溶,滤过,滤液减压回收乙醇,60℃以下真空干燥,即可得到延胡索季铵总碱。Corydalis medicinal material is crushed, passed through a 50-mesh sieve, soaked in 10 times the amount of 70% ethanol, and then subjected to 20KHz ultrasonic treatment for 120 minutes. The soaked medicinal material Corydalis Corydalis is placed in a microwave extraction tank for microwave extraction. The output power of the microwave is 650W. 65°C, irradiated for 10 minutes, extracted 3 times, combined the extracts, filtered to remove the medicinal residues; the filtrate recovered ethanol until it had no alcohol smell, and the liquid passed through the D151 weakly acidic cation exchange resin, and the flow rate of the liquid was absorbed and exchanged through the resin column 1.0 ml/min; after the exchange is completed, wash away the non-adsorbed impurities with water, elute with 20% ammonia alcohol solution, collect the ammonia alcohol eluate, use alkaloid reagent to detect during the elution process, and stop at the end of the elution Add the eluent, concentrate the eluent under reduced pressure, dry it in vacuum below 60°C, redissolve the dried product in 50% ethanol, filter, recover the ethanol from the filtrate under reduced pressure, and dry it under vacuum below 60°C to obtain the total quaternary ammonium corydalis. alkali.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007101874652A CN101278980A (en) | 2007-11-27 | 2007-11-27 | A kind of quaternary ammonium total alkali and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007101874652A CN101278980A (en) | 2007-11-27 | 2007-11-27 | A kind of quaternary ammonium total alkali and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101278980A true CN101278980A (en) | 2008-10-08 |
Family
ID=40011767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007101874652A Pending CN101278980A (en) | 2007-11-27 | 2007-11-27 | A kind of quaternary ammonium total alkali and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101278980A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102512416A (en) * | 2011-11-22 | 2012-06-27 | 浙江清华长三角研究院 | Medicine composition containing dehydrogenated corydaline as well as preparation method and measurement method |
CN109158096A (en) * | 2018-10-29 | 2019-01-08 | 江苏九九久科技有限公司 | Accelerate the method for macroporous resin adsorption and desorption rate |
CN116139197A (en) * | 2023-03-01 | 2023-05-23 | 岭南中药饮片有限公司 | Preparation method of vinegar-processed corydalis tuber formula granules |
-
2007
- 2007-11-27 CN CNA2007101874652A patent/CN101278980A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102512416A (en) * | 2011-11-22 | 2012-06-27 | 浙江清华长三角研究院 | Medicine composition containing dehydrogenated corydaline as well as preparation method and measurement method |
CN109158096A (en) * | 2018-10-29 | 2019-01-08 | 江苏九九久科技有限公司 | Accelerate the method for macroporous resin adsorption and desorption rate |
CN116139197A (en) * | 2023-03-01 | 2023-05-23 | 岭南中药饮片有限公司 | Preparation method of vinegar-processed corydalis tuber formula granules |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103393780B (en) | Extraction method of high-purity coptis total alkaloid | |
CN101260131A (en) | Method for extracting iridoid active site and monomer from Eucommia ulmoides | |
CN101653463B (en) | Extraction and purification method of tannin components in Geranium wilfordii | |
CN102526315B (en) | Preparation method of extracts of effective fractions of lychee seeds | |
CN102285994B (en) | Method for separating and purifying fangchinoline and tetrandrine from stephania tetrandra | |
CN102875562A (en) | Method for preparing psoralen and isopsoralen or extract containing psoralen and isopsoralen | |
CN102423329A (en) | Method for decoloring panax notoginseng saponins extracting solution | |
CN104644793A (en) | Efficient extraction method of total coptis alkaloids | |
CN102539588A (en) | Method for preparing test solution for quality detection of safe stagnation removing preparation | |
CN101278980A (en) | A kind of quaternary ammonium total alkali and preparation method thereof | |
CN100424085C (en) | Total alkaloid of xiatianwu (a Chinese medicinal material), its preparation method and application | |
CN104873570A (en) | Extracting and purifying method for prunella vulgaris total flavonoids and application of prunella vulgaris total flavonoids | |
WO2014000119A1 (en) | Anti-tachyarrhythmia formulation and preparation method thereof | |
CN103059037B (en) | A kind of method of Chelidonine in enriching and purifying greater celandine | |
CN102145040A (en) | Technique for adsorbing and extracting effective part of folium orthosiphoni by employing macroporous resin | |
CN101244124B (en) | Preparation method and application of active part of mulberry leaves | |
CN1241923C (en) | Method for extracting total alkaloid of corydalis rhizome and its new usage | |
CN111001189A (en) | Method for capturing and separating effective components in liquorice by using mixed-mode agarose gel medium | |
CN115006448A (en) | High-content rhizoma Menispermi total alkaloid and preparation method thereof | |
CN103083392A (en) | Method for separating and enriching part with prenylated flavonoid in subprostrate sophora | |
CN113413413A (en) | Preparation method and quality detection method of traditional Chinese medicine composition for treating cerebrovascular diseases through meridian rehabilitation method | |
CN103265549B (en) | A kind of method extracting protopine from honey raisin tree seven | |
CN102078400B (en) | Preparation method of extract of total triterpene acid of loquat leaf | |
CN113429442A (en) | Method for separating tectoridin and tectorigenin from rhizoma Belamcandae water extraction residues | |
CN111228407A (en) | Dendrobium officinale extract containing total phenanthrene compounds, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20081008 |